Medidata Rave Lite To Support Early, Late-stage Clinical Trials

KUALA LUMPUR, Oct 18 (Bernama) -- Medidata, a clinical trial solutions provider to the life sciences industry, has announced Medidata Rave Lite, an extension of its gold-standard clinical research software, Medidata Rave EDC, designed explicitly for Phase I and Phase IV studies.

“Rave Lite addresses a critical need in the market for early and late-stage trials, offering a streamlined solution built on our trusted Rave EDC platform.

“By giving our customers the ability to use one EDC ubiquitously across all phases, customers gain the flexibility to scale their studies while maintaining the high standards that have long defined Medidata’s solutions,” said its chief technology officer, Tom Doyle in a statement.

bootstrap slideshow

Rave Lite provides efficient electronic clinical data capture (EDC), management, and analysis solutions with a tailored pricing model, regardless of company size, therapeutic focus, or pipeline.

While EDC is a fundamental building block of clinical trials, technology fragmentation across phases leads to integration challenges and delays in startup times.

In particular, the lack of access to innovative technology disproportionately affects early- and late-stage studies. Having addressed these challenges in over 34,000 trials, Medidata is now offering superior options for Phase I and Phase IV studies with Rave Lite.

bootstrap slideshow

With Medidata Designer integration, study builders can design Phase I and Phase IV trials with speed and precision, and with the continued use of artificial intelligence, potential study misconfigurations are reduced while securing data integrity.

Thus, Rave Lite offers a consistent experience without sacrificing the advanced power of Rave EDC.

Medidata will showcase Rave Lite at NEXT New York, the premier clinical trials conference hosted by the company, in New York City on Nov 13 and 14, with the solution being made available to customers in early 2025.

-- BERNAMA